Irsogladine is a commonly used anti-gastric ulcer agent in Japan, and recent in vivo studies have shown it to have anti-angiogenic properties. The exact role of irsogladine as an inhibitor of angiogenesis remains uncertain. In this study, we show that irsogladine inhibited breast cancer regrowth and pulmonary metastasis but had no anti-angiogenic function against HUVEC cells. Irsogladine failed to inhibit proliferation, tubular formation, and the uPA/MMP-1 mRNA expression of HUVEC cells. We also examined the effect of irsogladine in an orthotopic transplant model of human breast cancer metastasis in athymic mice. Human MDA-MB-435 cells were injected into the mammary fat pads. After 9 weeks, the tumors were resected under general anesthesia. Irsogladine or vehicle was given p.o. daily thereafter. Daily administration of irsogladine at 120 mg/kg per day over a 5-week period had no effect on the body weight of the mice. Tumor regrowth, average volume of pulmonary metastases, and the number of metastases were inhibited by 40, 48 and 64%, respectively. These results suggest that irsogladine may be useful in the breast cancer adjuvant setting.
Introduction
New blood vessel formation (angiogenesis) is mandatory for growth of breast cancer, and the development within tumor tissues has been implicated in invasion and metastasis in breast cancer, melanoma, prostatic cancer, and other cancers [1, 2] . An effective vesseltargeting therapy should be useful for many types of cancer because delivering the drug to the vessels should be much easier than getting it into all the cells of a solid tumor. Several anti-angiogenic agents are currently undergoing clinical trials [3, 4] . These include interferons [5] , tetracycline [6] , tamoxifen [7] and thalidomide [8] .
Irsogladine has been clinically used as an antigastric ulcer agent in Japan, where it acts to strengthen intercellular gap junctions [9] . Irsogladine has been found to inhibit the induction of tissue-type plasminogen activator (tPA) synthesis in endothelial cells and angiogenesis in both in vitro and in vivo models [10] . Recently, irsogladine has also been shown to have anti-tumor activity in murine xenograft models of epidermoid cancer and glioma [11] . To date no work has been performed evaluating irsogladine in breast cancer. In the present study, we investigated the effect of irsogladine in a human breast cancerathymic nude mouse system [12] , specifically looking at local-regional tumor regrowth and the formation of pulmonary metastases after primary tumor resection.
Materials and methods

Cell culture and drugs
Human MDA-MB-435 breast cancer cells (a gift from Dr Janet Price, The University of Texas M.D. Anderson Cancer Center, Houston) were cultured in minimum essential medium (Life Technologies (GIBCO BRL), Gaithersburg, MD) supplemented with multi-vitamins, sodium pyrophosphate (100 mM), penicillin (10 5 U/100 ml), streptomycin (10 µg/100 ml) and fetal calf serum (5%) (supplements from Sigma Chemical Co., St. Louis, MO) in a 5% CO 2 -air atmosphere at 37 • C. The HUVEC umbilical vein cell kit and recombinant human vascular endothelial cell growth factor (VEGF) were obtained from Clonetics (San Diego, CA) and Genentech, Inc. (South San Francisco), respectively. Irsogladine and VEGF were freshly prepared for each experiment.
Cell proliferation assay
Cell proliferation was determined using the CellTilter Aqueous nonradioactive cell proliferation assay (Promega Corp., Madison, WI). Cultured cells (5 × 10 3 cells/well) were plated with various doses of irsogladine into 96-well tissue culture plates (Costar, Cambridge, MA). After 48 h, 20 µl/well of combined tetrazolium/phenazine methosulfate solution was added. After 60 min at 37 • C in a 5% CO 2 -air atmosphere, an absorbance reading at 450 nm was measured using Elx 800 (Bio-Tek Instruments, Inc., Winooski, VT). The results are reported as a percentage of untreated control cells. Each group has 8 wells.
Tubular formation assay
HUVEC cells (4 × 10 4 cells/well) were seeded on gels of growth factor reduced Matrigel matrix (Becton Dickinson, Bedford, MA) with or without VEGF (10 ng/ml) and/or irsogladine (100 µM) into 24-well tissue culture plates (Costar). After 24 h, microscopic pictures of each well were taken and the total length of tubular formation per field was measured using a road map pen (American Map, Maspeth, NY). Eight random fields were measured and the total length per field was calculated.
Northern blot analysis
HUVEC cells were incubated with or without VEGF (10 ng/ml) and/or irsogladine (100 µM) for 24 h. Total RNA was extracted and subjected to northern blotting as described previously [13, 14] . Briefly, the RNA was fractionated on 1% agarose gel containing 2.2 M formaldehyde, and transferred to an Optitran membrane (Schleicher and Schuell, Inc., Keene, NH). The membranes were baked in a vacuum oven at 80 • C, prehybridized, hybridized, washed, and exposed to an X-ray film with an intensifying screen at −80 • C.
The probes specific for human urokinase-type plasminogen activator (uPA), matrix metalloproteinase-1 (MMP-1) and β-actin were an 1.5 kb Pst I-Pst I fragment of pEMBL8, a 2.0 kb EcoRI-Pst I fragment of pSP64 and an 1.4 kb EcoRI-EcoRI fragment of pBluescript SK-, respectively. All plasmids were obtained from the American Type Culture Collection, Rockville, MD. After exposure to X-ray film and development, expression was measured densitometrically using Adobe Photoshop 4.0 (Adobe System, Inc., Seattle, WA). Relative levels of specific uPA and MMP-1 mRNA were compared after normalization by dividing each expression densitometrically by that of β-actin on the same filter.
Human breast cancer xenograft-nude mouse model
The nude mouse xenograft model was performed as described previously by Sledge et al. [12] . Briefly, female BALB/c nude mice (Harlan Sprague Dawley, Indianapolis, IN), 6-8 weeks old, were used. MDA-MB-435 cells (5 × 10 5 cells/mouse) were injected into the mammary fat pads of 40 nude mice. After 9 weeks, the tumors were resected under general anesthesia. Irsogladine, suspended in 0.5% sodium carboxymethylcellulose (vehicle), was given p.o. daily thereafter. The control mice were given only vehicle. The administrations were continued through week 14. The lungs were removed and fixed in Bouin's solution. Macroscopically visualized tumors Figure 1 . Effect of irsogladine on tubular formation by VEGF-treated HUVEC cells. HUVEC cells were seeded on gels of growth factor reduced Matrigel matrix with or without VEGF (10 ng/ml) and/or irsogladine (100 µM) into 24-well tissue culture plates. After 24 h, microscopic pictures of each well were taken and the total length of tubular formation per field was measured. Eight random fields were measured and the total length per field was calculated. Total length is represented as mean length ±SE. 
Results
Irsogladine has been shown to specifically inhibit proliferation of vascular endothelial cells [11] . We examined the effect of irsogladine on the proliferation of HUVEC and MDA-MB-435. Irsogladine at 100 µM inhibited the proliferation of HUVEC and MDA-MB-435 by 15% but had no effect at one and 10 µM (data not shown). There was no difference between the two cell lines. As shown in Figure 1 , VEGF induced tubular formation by HUVEC cells, but irsogladine did not block the stimulatory effect of VEGF. Although irsogladine has been found to inhibit the induction of tPA mRNA in epidermal growth factor (EGF) treated endothelial cells [10] , irsogladine has no effect on the uPA/MMP-1 cascade in HUVEC cells incubated without growth factors for 24 h in a serum-free medium (Table 1) . We have previously used an athymic mouse model of human breast cancer to evaluate the effect of antiangiogenic agents on tumor regrowth and metastasis [12] . Eight of 40 primary tumor-bearing mice died during tumor resection and 34 survival mice were used for the following study. Daily administration of irsogladine at 120 mg/kg per day over a 5-week period did not affect the body weight of the mice, though one of 18 control mice died before the study was completed. Primary tumor regrowth occurred in 14 of 16 irsogladine-treated mice and all of vehicle-treated controls. As shown in Table 2 , orally delivered irsogladine inhibited tumor regrowth by 40% of control.
As shown in Table 2 , daily treatment with irsogladine at 120 mg/kg per day decreased the incidence, the volume, and the number of pulmonary metastases. Only one of 17 control mice failed to develop pulmonary metastases, compared with 5 of 16 irsogladinetreated mice. Similarly, the volume and the number of metastases were inhibited by 48 and 64%, respectively ( Table 2) .
Discussion
In our laboratory, we have used a human breast cancerathymic nude mouse model system to evaluate the effect of adjuvant anti-angiogenic therapy after primary tumor resection [12] . In this system, tumor regrowth and spontaneous pulmonary metastasis were inhibited by irsogladine orally administered after primary tumor resection.
Irsogladine, which has been clinically used as an anti-gastric ulcer agent in Japan, has been reported to have efficacy in metastatic [15] and inoperable gastric cancer [16] when combined with UFT (a mixture of tegafur and uracil in a molar ratio of 1:4). Experimentally, irsogladine has been shown to inhibit angiogenesis [10, 11] and carcinogenesis [17, 18] .
Irsogladine, a potent inhibitor of angiogenesis, has been found to inhibit the induction of tPA mRNA in EGF-treated endothelial cells [10] . In human breast cancer, uPA rather than tPA has been shown to play a more important role both in tumor-related angiogenesis and as a prognostic agent [19] , and MMPs have been shown to be involved in endothelial cells during the angiogenic process [20, 21] . We examined the hypothesis that irsogladine might affect the uPA/MMP cascade in vascular endothelial cells. Irsogladine failed to inhibit proliferation, tubular formation, and the uPA/MMP-1 mRNA expression of human vascular endothelial cells. These results suggest that HUVEC cells might be not responsive to irsogladine.
Sato et al. [10] have suggested that an antiangiogenic effect of irsogladine may be general and not restricted to the effect of EGF. The reason was that the angiogenic potential of human omental microvascular endothelial cells, which had not produced EGF [22] , was not related to EGF. Ren et al. [23] have suggested that the mechanism may be independent of plasminogen activation in vivo because the agent inhibited bFGF-induced angiogenesis in tPA-knockout and uPA-knockout mice. In addition, irsogladine has been reported to upregulate intercellular communication via gap junctions between cultured rabbit gastric endothelial cells [9] , and the junctional communication has been reported to be induced in migrating vascular endothelial cells [24] . Irsogladine upregulated expressions of connexin26 and 32, gap junction proteins, in the rat liver [25] . These findings suggest that the modulation of gap junctional intercellular communication by irsogladine might correlate to its anti-angiogenic effect, but the exact role of irsogladine as an inhibitor of angiogenesis remains uncertain.
Irsogladine modestly inhibited not only tumor regrowth of MDA-MB-435 mammary fat pad tumors but pulmonary metastases and might be a unique and useful drug in treatment of breast cancer adjunctive to surgery. Further study is required to clarify the mechanism by which irsogladine inhibits the tumor regrowth and metastasis.
